An update on the ophthalmic features in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)

Int Ophthalmol. 2022 Jun;42(6):1987-1995. doi: 10.1007/s10792-021-02197-y. Epub 2022 Jan 16.

Abstract

Hereditary haemorrhagic telangiectasia (HHT) or Osler-Rendu-Weber syndrome is a rare autosomal dominant disease, characterised by systemic angiodysplasia. Dysfunction of the signalling pathway of β transforming growth factor is the main cause of HHT principally owing to mutations of the genes encoding for endoglin (ENG) and activin A receptor type II-like 1 (ACVRL1). Clinical manifestations can range from mucocutaneous telangiectasia to organ arterio-venous malformations and recurrent epistaxis. The early clinical manifestations may sometimes be subtle, and diagnosis may be delayed. The main ophthalmic manifestations historically reported in HHT are haemorrhagic epiphora, and conjunctival telangiectasia present in 45-65% of cases, however, imaging with wide-field fluorescein angiography has recently shown peripheral retinal telangiectasia in 83% of patients. Optimal management of HHT requires both understanding of the clinical presentations and detection of early signs of disease. Advances in imaging methods in ophthalmology such as wide-field fluorescein angiography, spectral domain optical coherence tomography, and near infrared reflectance promise further insight into the ophthalmic signs of HHT towards improved diagnosis and early management of possible severe complications.

Keywords: Hereditary haemorrhagic telangiectasia; Multimodal imaging; Near infrared reflectance; Ophthalmic; Rendu-Osler-Weber syndrome; Spectral domain optical coherence tomography; Wide-field fluorescein angiography.

Publication types

  • Review

MeSH terms

  • Activin Receptors, Type II / genetics
  • Endoglin / genetics
  • Eye
  • Eye Diseases* / etiology
  • Humans
  • Mutation
  • Telangiectasia, Hereditary Hemorrhagic* / complications
  • Telangiectasia, Hereditary Hemorrhagic* / diagnosis

Substances

  • Endoglin
  • ACVRL1 protein, human
  • Activin Receptors, Type II